Sirnaomics reveals dose administration of 1st patient in STP705 trial
Category: #health  By Pankaj Singh  Date: 2021-01-18
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Sirnaomics reveals dose administration of 1st patient in STP705 trial

Sirnaomics, Inc., a clinical-stage biopharmaceutical company, has recently announced the dose administration of the 1st patient in a Phase 2a clinical trial of STP705. STP705 is a lead drug candidate developed by the company for use against cutaneous basal cell carcinoma.

This open-label, dose-escalation clinical study is designed with an objective to examine the safety and efficacy of the intralesional injection of STP705 among adult patients suffering from cutaneous basal cell carcinoma (BCC) that was confirmed with biopsy samples. The trial will also analyze the biomarkers common to the BCC formation pathway such as COX-2 and TGF-β1.

The Phase 2a clinical trial comprises of 3 dose-escalation cohorts that range from 30 μg to 90 μg with 5 patients in each group. The participants will receive STP705 injection once a week for over 6 weeks. Its primary endpoint of the study is to evaluate a complete histological clearance of the patients’ tumor cells within the BCC lesion. On the other hand, the secondary endpoint is to examine patients for the investigational product treatment related to various adverse events as well as cutaneous skin reactions.

As per the statement made by Sirnaomics’ CEO, President, & Founder, Patrick Lu, Ph.D., the recent dose administration announcement marks a significant milestone as the company targets to advance its oncology therapeutic candidate pipeline. The company has also been continuously leveraging the polypeptide nano-particle technology for the siRNA drug delivery. It is looking forward to receiving the key clinical readouts through this trial, maintaining its leadership position in the RNAi therapeutic development for treating skin cancers.

According to Sirnaomics’ Chief Medical Officer, Michael Molyneaux, M.D., the recent STP705 program to evaluate patients with BCC is expected to offer an alternative treatment to the surgical excision of the lesions. This trial will also help meet the high unmet needs for the non-surgical treatments of several non-melanoma skin cancer types.

Sirnaomics is anticipated to release the initial clinical trial data in 2021.

Source credit:
https://www.benzinga.com/pressreleases/21/01/n19196774/sirnaomics-announces-first-patient-dosed-in-phase-2a-study-of-stp705-for-treatment-of-cutaneous-ba



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

PCS Software adds new contactless features to expand TMS platform

PCS Software adds new contactless features to expand TMS platform

By Pankaj Singh

  • With this addition, it is now possible for PCS consumers to effectively manage their workflows using their mobile devices
  • Document digitization has...

ODP teams up with Microsoft to support shared & new B2B customers

ODP teams up with Microsoft to support shared & new B2B customers

By Pankaj Singh

The ODP Corporation, an American retail company, has recently announced the expansion of its long-standing relationship with Microsoft. The two companies are planning to boost efficiencies and growth of their shared as...

Gannex reveals positive data from ASC41 clinical study in 20 subjects

Gannex reveals positive data from ASC41 clinical study in 20 subjects

By Pankaj Singh

Ascletis Pharma Inc.’s wholly-owned company, Gannex, has reportedly announced the positive clinical data from its ASC41 trial conducted among overweight and obese subjects. The active metabolite of this liver-tar...